Patents Assigned to Therabrake, Inc.
  • Method and system to provide personalized pharmaceutical compositions and dosages
    Patent number: 8999721
    Abstract: Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio. The Fayad/Schentag index is used in scoring cardiovascular risks of Metabolic Syndrome patients and for recommending and implementing therapeutic interventions that can be shown to lower cardiovascular risk.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: April 7, 2015
    Assignee: Therabrake, Inc.
    Inventors: Jerome J. Schentag, Joseph M. Fayad, Scott V. Monte